1. The use of PBPK modeling across the pediatric age range using propofol as a case

   • Robin Michelet
   • Jan Van Bocxlaer
   • An Vermeulen

   Original Paper 08 October 2018 Pages: 765 - 785

   

2. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues

   • Silvia Maria Lavezzi
   • Enrica Mezzalana
   • Monica Simeoni

   Original Paper 10 November 2018 Pages: 787 - 802

   

3. Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure–response modeling of Mayo scores for golimumab in patients with ulcerative colitis

   • Chuanpu Hu
   • Omoniyi J. Adedokun
   • Honghui Zhou

   Original Paper 30 October 2018 Pages: 803 - 816

   

4. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans

   • Konstantinos Biliouris
   • Ivan Nestorov
   • Mirjam N. Trame

   Original Paper 30 October 2018 Pages: 817 - 827

   

5. Modeling the acute effects of exercise on insulin kinetics in type 1 diabetes

   • Spencer Frank
   • Abdulrahman Jbaily
   • Andrew J. Szeri

   Original Paper 03 November 2018 Pages: 829 - 845